EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers

David J Stewart, Katherine Cole iD, Dominick Bosse iD, Stephanie Brule, Dean Fergusson, Tim Ramsay

Current Oncology · 2024

DOI: 10.3390/curroncol31030122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von David J Stewart und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Acrylamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Using digitized data from progression-free survival (PFS) and overall survival Kaplan–Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR-mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log–linear curve shape and estimation of the proportion of patients cured, PFS half-lives for subpopulations destined to eventually relapse, and probability of eventual relapse in patients remaining progression-free at different time points. The proportion of patients potentially cured was 41% for adjuvant controls, 58% with adjuvant chemotherapy, 17% for ADAURA controls, not assessable with adjuvant osimertinib, 15% with chemoradiotherapy, and 12% for SCLC. Median PFS half-life for relapsing subpopulations was 11.9 months for adjuvant controls, 17.4 months with adjuvant chemotherapy, 24.4 months for ADAURA controls, not assessable with osimertinib, 9.3 months with chemoradiotherapy, and 10.7 months for SCLC. For those remaining relapse-free at 2 and 5 years, the cure probability was 74%/96% for adjuvant controls, 77%/93% with adjuvant chemotherapy, 51%/94% with chemoradiation, and 39%/87% with limited SCLC. Relatively easy population kinetic analyses add useful information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaAcrylamidesAniline CompoundsIndolesPyrimidinesHumansNeoplasm StagingNeoplasm Recurrence, LocalRecurrence

Stichwörter der Autor:innen

lung cancerpopulation survival kineticsprogression-free survivaltutorial on population survival kinetics

Substanzen

osimertinibAcrylamidesAniline CompoundsIndolesPyrimidines

Autor:innen und Institutionen

  • Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143, USA.

ORCID-Profile: Katherine Cole, Dominick Bosse

Zitieren

APA

Stewart, D. J., Cole, K., Bosse, D., Brule, S., Fergusson, D., & Ramsay, T. (2024). Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers. Current Oncology. https://doi.org/10.3390/curroncol31030122

Vancouver

Stewart DJ, Cole K, Bosse D, Brule S, Fergusson D, Ramsay T. Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers. Current Oncology. 2024. doi:10.3390/curroncol31030122

BibTeX
@article{Stewart2024,
  author = {Stewart, David J and Cole, Katherine and Bosse, Dominick and Brule, Stephanie and Fergusson, Dean and Ramsay, Tim},
  title = {Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31030122}
}
Kostenlos starten →